A. InTandem, a Delaware limited liability company formed in January 2012, is an investment adviser located in New York, NY. The Firm’s principal owner is Elliot Cooperstone. B. Firm provides investment advisory services to private pooled investment vehicles including InTandem Capital Partners Fund, L.P. (“ICP”), InTandem Capital Partners Fund II, LP (“ICP II Master”), InTandem Capital Partners Fund II Blocker Feeder, LP (“ICP II Feeder,” and together with ICP II Master, “ICP II”), InTandem Capital Opportunities Fund, LP (“ICO”), InTandem Capital Partners Fund III, LP (“ICP III Main”) and InTandem Capital Partners Fund III-A, LP (“ICP III Blocker,” and together with ICP III Main, “ICP III,” and together with ICP, ICP II and ICP III, the “ICP Funds”), ITC Rumba, LLC (“ITC”), ITC (PHS) Parallel Fund, LP (“PHS I”), ITC PHS Co-Invest II, LP (“PHS II,” and together with PHS I, “PHS”), ITC Rumba Co-Invest, LP (“ITC Co-Invest”), ITC Stork Co-Invest, LP (“Stork I”), ITC Stork Co-Invest II, LP (“Stork II,” and together with Stork I, “Stork”), ITC Infusion Co-Invest, LP (“Infusion”), ITC HouseWorks Co-Invest, LP (“HouseWorks Main”), ITC HouseWorks Co-Invest A, LP (“HouseWorks Blocker,” and together with HouseWorks Main, “HouseWorks”), ITC Ortho Co-Invest, LP (“Ortho Main”), ITC Ortho Co-Invest A, LP (“Ortho Blocker,” and together with Ortho Main, “Ortho), and ITC TAMF Co Invest, LP (“TAMF,” and with the ICP Funds, ITC, PHS, ITC Co-Invest, Stork, Infusion, HouseWorks and Ortho, collectively, the “Funds”). The Funds execute lower middle market “buy and build” strategies in niche healthcare services sectors positioned to benefit from demographic growth trends and industry consolidation with certain Funds acting as lead equity sponsors in executing such strategies. InTandem is affiliated with InTandem Fund GP, L.L.C. (“GP”), the general partner to ICP and PHS; ITC Rumba Manager, LLC (“Managing Member”), the managing member to ITC and the general partner to ITC Co-Invest; InTandem Fund GP II, LLC (“GP II”), the general partner to ICP II and Stork I; InTandem Stork II GP, LLC (“GP Stork II”), the general partner to Stork II; InTandem Opportunities Fund GP, LLC (“GPO”), the general partner to ICO; InTandem Infusion Co-Invest GP, LLC (“GP Infusion”), the general partner to Infusion; and InTandem Fund GP III, LP (“GP III”), the general partner to ITC III, TAMF, HouseWorks and Ortho (GP, GP II, Managing Member, GP Stork II, GPO, GP Infusion and GP III are collectively referred to herein as the “General Partners”). Given the Firm’s strategy to invest in “buy and build” platform investments, and the potential for growth through add-on acquisitions, the Firm anticipates that there may be

co-investment opportunities (“Co- investments” or “Co-invests”) that can be offered to investors in the Funds (“Investors” or “Limited Partners,” and together with the General Partner(s), “Partners”)) and other strategic investors, including other sponsors, market participants, finders, consultants and other service providers, portfolio company management or personnel, InTandem personnel, and/or certain other persons associated with InTandem and/or its affiliates (e.g., a vehicle formed by InTandem’s principals to co-invest alongside a particular Fund’s transactions). Such Co-investments typically involve investment and disposal of interests in the applicable portfolio company (“Portfolio Company”) at the same time and on the same terms as the Fund making the investment. However, for strategic and other reasons, a co-investor or Co-invest vehicle (including a co-investing Fund) purchases a portion of an investment from one or more Funds after such Funds have consummated their investment in the Portfolio Company (also known as a post-closing sell- down or transfer), which generally will have been funded through Fund investor capital contributions and/or use of a Fund credit facility. Any such purchase from a Fund by a co-investor or Co-invest vehicle generally occurs shortly after the Fund’s completion of the investment to avoid any changes in valuation of the investment, but in certain instances could be well after the Fund’s initial purchase. Where appropriate, and in InTandem’s sole discretion, InTandem reserves the right to charge interest on the purchase to the co- investor or Co-invest vehicle (or otherwise equitably to adjust the purchase price under certain conditions), and to seek reimbursement to the relevant Fund for related costs. However, to the extent that any such amounts are not so charged or reimbursed, they generally will be borne by the relevant Fund. The information provided herein about the investment advisory services provided by InTandem is qualified in its entirety by reference to the Offering Documents. C. InTandem does not tailor advisory services to the individual or particular needs of the Investors. Such Investors accept the terms of advisory services as set forth in the Offering Documents. The Firm has broad investment authority with respect to the Funds and, as such, Investors should consider whether the investment objectives of the Funds are in line with their individual objectives and risk tolerance prior to investment. D. InTandem does not participate in wrap fee programs. E. As of December 31, 2023, InTandem managed approximately $1,961,400,000 in client assets, all on a discretionary basis.